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Abstract
Background: Organized cervical cancer screening services are presently lacking in Nigeria contributing to late
presentation and diagnosis of invasive cervical cancer cases (ICCs) at advanced stages in most gynecologic
units in Nigeria. We evaluated outcomes of ICCs diagnosed at Jos University Teaching Hospital (JUTH) to
better understand factors associated with cervical cancer survival in similar resource limited settings.
Methods: We performed a retrospective cohort study with a prospective follow up data to estimate time
from diagnosis to mortality among women diagnosed with ICCs at JUTH. Women who were diagnosed with
ICCs between January 2011 and May 2013 were followed up after initial evaluation at JUTH and subsequent
referral for specialized treatment in one of the national oncology treatment centers in Nigeria. The main
outcome measured was all-cause mortality rate and overall survival (OS) after diagnosis of ICC. The follow up
data were updated and observations were censored March 31, 2015. The overall death rate was estimated
using the total number of death events and the cumulative follow-up time from diagnosis to death. We
conducted Cox proportional hazard regression to assess factors associated with death.
Results: A total of 65 histologically confirmed ICCs were followed up. The median age of the cohort was
50 years with a median parity of 7. The HIV prevalence in the cohort was 8.2 % and the majority (72.3 %)
were diagnosed at advanced stages (AD) of ICC. Simple total abdominal hysterectomy (TAH) was performed
in 38.9 % of patients who were diagnosed at early stage disease (ED). After a cumulative follow up of
526.17 months, 35 deaths occurred with an overall death rate of 79.8 per 100 women-years. We also found
a significantly higher hazard of death in women with AD (HR = 3.3) and baseline anemia (HR = 3.0). In the
subgroup of women with ED, the OS was significantly higher for those who had TAH compared to those
who did not (26.5 versus 11.6 months respectively).
Conclusion: Advanced stage disease and baseline anemia were independently associated with higher death
rate. Cervical cancer patients diagnosed at early stages by non-oncologic specialist in settings lacking the
standard of care may benefit from improve survival with simple hysterectomy.
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Background
With over 528,000 new cases of invasive cervical cancer
(ICC) and 266,000 deaths reported annually, it is the
fourth most common cancer in women worldwide [1, 2].
Cervical cancer screening programs have led to a sus-
tained decline in cervical cancer incidence and mortality
in developed countries and prevented premature deaths
in underserved populations [3, 4]. This is attributable
in part to early detection of invasive cervical cancer,
thereby improving survival following treatment [5].
In contrast to the trend in developed countries, Nigeria
and other countries in sub-Saharan Africa with limited
cervical cancer screening programs are experiencing an
upsurge in ICC cases [6]. Indeed, almost 70 % of the
global burden of cervical cancer resides in these countries
[2]. Cervical cancer screening helps in identifying precan-
cerous conditions of the cervix in asymptomatic women
at risk, the treatment of which halts progression to inva-
sive stages. Therefore, Cervical cancer screening does not
only lead to significant reduction in incident cases of
cancer, but has the additional benefit of providing oppor-
tunities for early detection of new cases thereby improving
prognosis for survival following treatment. The glooming
disparities in cervical cancer incidence and mortality be-
tween the developed and developing countries are further
evident in the recent global cancer statistics reporting
34.8 new cases and 22.5 deaths from cervical cancer
per 100,000 women annually in sub-Saharan Africa [1],
compared to North America with a cervical cancer annual
incidence of 6.6 per 100,000 women and a mortality of 2.5
per 100,000 women.
The absence of organized cervical cancer screening
services in Nigeria, often leads to ICC cases presenting
at advanced stages in health facilities lacking infrastruc-
ture for effective treatment [7–9]. This situation often
limits available care in such hospitals to initial evaluation,
symptomatic treatment and referral [7, 9] of confirmed
ICCs to the few national treatment centers with chemo-
radiation facilities within the country.
In this report, we present descriptive epidemiologic
data on cervical cancer patients diagnosed and treated
by non-oncologists at a tertiary medical center with
limited treatment facilities in Nigeria. Follow up data
documenting survival and mortality rates from ICCs are
rare in such clinical settings. Therefore, the report is
focused on survival of ICC cases and the challenges of
managing such cancers in our environment.
Methods
Study setting and design
We performed a retrospective cohort study with a pro-
spective follow up data estimating time from diagnosis
to death among women diagnosed with ICC in the de-
partment of obstetrics and gynecology of Jos University
Teaching Hospital (JUTH), north central Nigeria. Women
with histologic diagnosis of cervical cancer between
January 2011 and May 2013 were included in the study
and followed from diagnosis to death, last follow-up or
loss to follow up.
Diagnosis of cervical cancer and initial assessments
Diagnostic evaluation of suspected cases of cervical can-
cer included examination under anesthesia (EUA) during
which clinical staging was made based on the Inter-
national Federation of Gynecology and Obstetrics pre-
2009 revision [10]. Cervical biopsies were obtained for
histopathologic confirmation and grading (well-differen-
tiated, moderately differentiated or poorly differentiated).
Histologic types were categorized as squamous cell carcin-
oma, adenocarcinoma or adenosquamous cell carcinoma.
Each diagnostic evaluation also included baseline hemo-
gram (Packed Cell Volume), HIV screening (Rapid Deter-
mine Test), renal and liver function assessment. Patients
also had abdominal and pelvic ultrasound scans, chest
X-rays and pre-operative/pre-radiation intravenous uro-
gram (IVU).
Management of cervical cancer, follow up and main
outcome
Throughout the study period, our institution did not
have facilities for chemo-radiation and we did not have a
trained medical or gynecologic-oncologist in cervical
cancer treatment. Due to this limitation, cervical cancer
patients received either symptomatic care (including
correction of anemia, treatment of infections, and pain
control) or referral to Ahmadu Bello University Teach-
ing Hospital (ABUTH), Zaria for chemo-radiation.
ABUTH is a tertiary academic medical center equipped
with facilities for chemo-radiation located approximately
300 kilometers north-west of Jos. A fraction of the pa-
tients who presented in early stages (FIGO stages 1-2A)
had simple total abdominal hysterectomy (TAH) per-
formed at the discretion of the attending gynecologist.
Simple total abdominal hysterectomy here refers to re-
moval of the uterus with the cervix and upper vaginal cuff
without lymph node dissection. All diagnosed ICCs were
offered referral to a chemo-radiation treatment facility
irrespective of stage at diagnosis or hysterectomy.
Follow up data were obtain from the gynecology out-
patient clinic records and via phone calls (patient’s and
next-of-kin phone contacts were obtained at diagnosis)
to ascertain if chemo-radiation was received after refer-
ral to ABUTH. The primary outcome measured was
all-cause mortality determined by the occurrence of
death following ICC diagnosis within the period of
follow up. Time from diagnosis to death (event) or last
follow-up, loss to follow up, and March 31, 2015 (cen-
sor) was calculated to determine overall mortality rate
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and survival probabilities for various factors in the
cohort.
Data collection
Demographic, clinical, laboratory, follow up and out-
come data were captured in case report forms from the
following source documents: individual case files, histo-
pathologic database, nurses’ in-patient notes and hospital
discharge summaries. Study variables were entered into an
excel spreadsheet and relevant variables were coded for
subsequent statistical analyses. The time from diagnosis to
mortality was calculated in days and subsequently con-
verted to weeks and lunar months. Patients who did not
return to the gynecology clinic and we could not contact
on the phone nor ascertain whether they were still alive or
had died were considered lost to follow up with observa-
tions censored at the last known status date. For this
group of patients, we calculated the time from diagnosis
to the last date we had information on their survival.
Statistical analyses
The analytical focus of this study was to determine the
all-cause mortality rate and to identify predictive factors
that contributes to mortality following diagnosis of
cervical cancer given our limited treatment facilities.
We generated summary descriptive characteristics using
means, medians and proportions where applicable. We
compared demographics and clinical characteristics of the
patients who were lost to follow up with those who com-
pleted follow up with outcome ascertainment. Bivariate
statistical analyses of the association between baseline
characteristics of the study sample and death were per-
formed using student t-test for means of continuous
variables and the Pearson chi square or Fisher’s exact tests
where applicable for categorical variables. All statistical
tests were 2-sided with type 1 error set at 0.05 for statis-
tical significance. To conduct bivariate analyses as well
as for the multivariate analyses, cervical cancer FIGO
staging was dichotomized to “early” (FIGO Stages IIA
or less) and “advanced” (FIGO Stages IIB and greater).
Baseline hemogram was similarly dichotomized into
baseline anemia (PCV <30 %) and normal hemogram
(PCV ≥30 %). Chemo-radiation, TAH, HIV status and
mortality were treated as binary variables for determin-
ing predictors of death. The overall death rate was
estimated using the total number of death events and
the cumulative follow-up time from diagnosis to death.
We also estimated the rate ratio of death for various
factors in the cohort. To estimate the hazard of death
following cervical cancer diagnosis, we used time from
diagnosis to death in months as a time covariate and
death as failure event. Bivariate and multivariate Cox
hazard regression modeling were performed to estimate
the hazards of death. We also plotted relevant Kaplan-
Meier survivor curves to estimate the probability of
survival following cervical cancer diagnosis by stage of
diagnosis and baseline anemia. We used the Log-Rank
test to assess the equality of survival function with
p-value <0.05 signifying significant difference in sur-
vival. Our final predictive model was selected by back-
ward variable selection method. Statistical analyses were
performed with STATA version 11.0, College Station,
Texas, USA.
Ethical consideration and approval
This study was approved by the Institutional Health Re-
search Ethical Committee of the Jos University Teach-
ing Hospital, Jos (Approval Ref #: JUTH/DCS/ADM/
127/XIX/6019).
Results
Baseline demographic and clinical characteristics
Between January 2011 and May 2013, 72 cases of sus-
pected cervical cancer were evaluated and managed at
JUTH. Sixty-five cases were histologically confirmed and
included in this analysis. The median age of the cohort
was 50 years with interquartile range (IQR) of 41–60),
and median parity of 7 (IQR 5–9). A majority of the
patients (72.3 %) were diagnosed at FIGO advanced
stages (2B and above) with a median PCV of 28 % (IQR
22.5-35.5). The proportions of the various stages are
summarized graphically in Fig. 1 (stage 1a (1.5 %), stage
1b (6.1 %), stage 2a (20.0 %), stage 2b (35.4 %), stage 3a
(9.2 %), stage 3b (24.6 %) and stage 4a (3.1)). Of the 65
patients diagnosed, we had HIV status data on 61 and
the prevalence was 8.2 %. The histologic types were
squamous cell carcinoma (91.0 %), and the predominant
histologic grade was moderately differentiated (58.0 %).
Other histologic types reported included adeno-squamous
cell carcinoma (5.0 %), adeno-carcinoma (2.0 %) and large-
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Count of Stage at diagnosis
Fig. 1 Bar chart of stages of cervical cancer at diagnosis in Jos Nigeria
Musa et al. Infectious Agents and Cancer  (2016) 11:15 Page 3 of 7
Clinical intervention after diagnosis
Eighteen (27.7 %) of the 65 cervical cancer patients were
diagnosed and categorized as early stage ICC. Of this
category, 38.9 % (7/18) had TAH as part of their man-
agement at JUTH. There was one case of hysterectomy
for advanced disease (FIGO stage 2B) and 1 patient had
a laparotomy with a pre-operative staging of FIGO 1B,
but tumor was considered inoperable. Sixty-two of the
65 patients offered referral accepted to go to ABUTH
for chemo-radiation treatment. Of these 62, 17.7 % (11
out of 62) reported ever receiving any further therapies
at the referring hospital (ABUTH). Reported reasons
(results not shown) for not receiving chemo-radiation
following referral included lack of finances to pay for the
service, decision to try traditional medications or seek
spiritual care and preference to continue supportive care
at JUTH or return to their homes.
Time to death following cervical cancer diagnosis
Of the 65 that were followed up, 47 (72.3 %) had
complete data on time from diagnosis to death and the
remaining 18 (27.7 %) had incomplete follow-up data.
The total accrued follow-up time from the 65 ICCs in
the study was 526.17 months; 35 death events occurred
with an all-cause death rate of 79.8 per 100 women-
years of follow up after ICC diagnosis. Death rate was
significantly higher among women with advanced ICC
(rate ratio = 4.7, 95 % CI: 2.0, 12.8, p-value 0.001) and
those with baseline anemia (rate ratio = 4.8, 95 % CI:
2.3–10.4, p-value 0.001). There was significantly lower
death rate for those who had chemo-radiation compared
with those who did not (rate ratio = 0.33, 95 % CI: 0.11,
0.81, p-value 0.007). In the subgroup of women who
were diagnosed at early stage ICC, the mean time from
diagnosis to death was significantly longer for those who
had TAH compare to those who did not (26.5 versus
11.6 months respectively, p-value 0.014).
Over two-thirds (68.1 %) of our cohort died after a mean
follow up time of 8.3 ± 10.8 months. There was a signifi-
cantly higher proportion of death in those diagnosed at
advanced stages compared to early stages (87.5 % versus
46.7 %, p-value 0.009). The mean time to death for
advanced disease was 6.9 ± 7.0 months versus 23.7 ±
12.7 months for early disease (p-value 0.001). Table 1
summarizes the association between baseline patients’
characteristics and death after diagnosis of ICC.
Factors predictive of death
In a Cox regression model, after a total follow up time
of 537.1 months, 35 deaths occurred out of the 65 ICCs
diagnosed at JUTH. The unadjusted model showed a
statistically higher hazard of death in patients with ad-
vanced disease (HR = 3.9, 95 % CI: 1.7, 9.2, p-value
0.002), and baseline anemia (HR = 3.7, 95 % CI: 1.8, 7.5,
p-value 0.001). Chemo-radiation showed a trend towards
reduced hazard of mortality (HR = 0.45, 95 % CI: 0.19,
1.12, p-value 0.088). In the adjusted model including
stage at diagnosis, baseline anemia and chemo-radiation;
advanced disease and baseline anemia were independently
associated with significant hazards of death after diagnosis
of ICC (HR = 3.3, 95 % CI: 1.2–8.9, p-value 0.021 and HR=
3.0, 95 % CI: 1.4, 6.4, p-value 0.006) respectively (Table 2;
Figs. 2 and 3). Additionally, Fig. 4 showed the observed
and predicted survival probability for early and advanced
ICCs. The predicted 2-year survival probability was about
15 % for advanced and 50 % for early disease in our
cohort.
Discussion
In this retrospective cohort study at a tertiary hospital in
Jos Nigeria, a total of 65 cases of cervical cancer were
diagnosed over a 28-month period, 72.3 % of which were
in advanced stages at presentation. This result reflects
the enormous burden of late presentation of ICCs in a
Table 1 Bivariate analyses of the association between patients’
baseline characteristics and mortality from ICCs, Jos Nigeria
Variable Dead Alive P-value
Mean Age (yrs) 49.5 ± 12.0 54.4 ± 12.3 0.228*
Mean Parity 6.3 ± 3.1 7.0 ± 2.6 0.458*
Disease stage
Advanced 28 (87.5) 4 (12.5) 0.009**
Early 7 (46.7) 8 (53.3)
Chemo-radiation
Yes 6 (54.5) 5 (45.5) 0.094***
No 28 (80.0) 7 (20.0)
HIV status
Positive 4 (80.0) 1 (20.0) 0.743**
Negative 30 (73.2) 11 (26.8)
Anemia
Yes 22 (91.7) 2 (8.3) 0.008**
No 13 (56.5) 10 (43.5)
Follow-up time (Months) 6.9 ± 7.0 23.7 ± 12.7 0.001*
*Student t-test, **Fisher exact test, ***Pearson chi square test
Table 2 Unadjusted and adjusted Cox regression analyses of






Advanced stage 3.9 (1.7, 9.2) 0.002 3.3 (1.2, 8.9) 0.021
Baseline anemia 3.7 (1.8, 7.5) 0.001 3.0 (1.4, 6.4) 0.006
Chemo-radiation 0.45 (0.19, 1.12) 0.088 0.9 (0.3, 2.4) 0.815
HIV positive 1.33 (0.46, 3.81) 0.586
HR hazard ratio, CI confidence interval
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tertiary academic medical center with limited oncologic
treatment facilities. This finding of late presentation is
consistent with a study done in Lagos, Nigeria which
found that less than 10 % of cervical cancer patients
presented at operable stages with the majority present-
ing with advanced disease [11]. Similarly, a clinico-
pathological analysis of cervical cancer seen in a tertiary
health facility in south-eastern Nigeria found that 89.3 %
of the patients presented at advanced stages [12]. Other
related studies in northern Nigerian settings have docu-
mented advanced disease at presentation in 66 %–81 % of
cervical cancer patients [13, 14]. These studies highlight
the huge challenge posed by late presentation of cervical
cancer in a country with very limited treatment facilities
and few trained gynecologic oncology specialists. Patients
diagnosed at advanced stages have few treatment options
and are often limited to either chemo-radiation or pallia-
tive care. Authors working in similar settings in Nigeria
have documented that even patients diagnosed at early
stages often do not have the benefits of surgical interven-
tion partly due to a dearth of skilled gynecologic surgical
oncologists [9].
We also found that over two-thirds (68.1 %) of our co-
hort had died after a mean follow up of 8.3 ± 10.8 months
following diagnosis of cervical cancer. A retrospective
review of cancer mortality over a 5 year period in a sin-
gle tertiary institution in Nigeria revealed that cervical
cancer was responsible for 44.7 % of all gynecologic can-
cer mortality during the study period and over 60.6 % of
the deaths occurred within 4 weeks of diagnosis [8]. Our
study findings showing a high proportion of mortality
with a death rate of 79.8 per 100 women-years of follow
up further revealed the dismal survival probability for
cervical cancer in our institution and in similar settings
in Nigeria.
In our predictive model of the factors related to cervical
cancer mortality, we found that advanced stage and base-
line anemia where significantly associated with hazard of
mortality. Mortality in those diagnosed at advanced stages
compared to early stages was 87.5 % versus 46.7 % with a
mean time to mortality for advanced disease of 6.9 ±
7.0 months versus 23.7 ± 12.7 months for early disease.
In the Cox regression model, we found that the pre-
dicted 2-year survival probability was about 15 % for
advanced disease and 50 % for early disease (Fig. 4). Our
predicted survival probability was similar to a Kenyan
study which showed a progressively lower survival prob-
ability with advancing stage of disease at diagnosis with an
overall predicted 2-year survival of less than 20 % [15].
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disease stage and survival of cervical cancer
Fig. 2 Kaplan Meier graph for survival probabilities of cervical cancer
stages at diagnosis in Jos Nigeria. Early cervical cancer is represented
with “staging = 0” and Advanced cervical cancer is represented with
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time from diagnosis to mortality (months)
Anemia = 0 Anemia = 1
Baseline anemia and survival of cervical cancer
Fig. 3 Kaplan Meier graph for survival probabilities of cervical cancer
by baseline anemia status in Jos Nigeria. Cervical cancer patients
with baseline anemia (PCV <30 %) at diagnosis is represented with
“Anemia = 1” and patients who had normal hemogram (PCV ≥30 %)
is represented with “Anemia = 0”. Log-Rank p-value 0.0002
Fig. 4 Kaplan Meier graph of observed and predicted survival
probabilities for cervical cancer in Jos Nigeria. Early stage cervical
cancer is represented with “Staging = 0” and Advanced stage
cervical cancer is represented with “staging = 1”
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15.0 months following diagnosis and concurrent chemo-
radiation therapy at a cervical cancer treatment center.
The mean age at diagnosis of our study sample was
50 years and 27.7 % were diagnosed at early stages out
of which 38.9 % had simple hysterectomy prior to refer-
ral for chemo-radiation. Although our study was not
designed to evaluate the effect of surgery on survival, we
observed from our data a potential benefit of simple
hysterectomy on survival in patients presenting in our
setting in early stages of cancer. The mean survival time
for early stage ICCs who had simple hysterectomy was
26.5 months compared to 11.6 months for early stage
ICCs who did not have hysterectomy (P-value 0.014).
Indeed, the role of surgery and the extent to which it
should be done for early stage cervical cancer has been a
subject of ongoing controversy. There is a growing
volume of evidence supporting the practice of minimal
surgical resection (i.e. simple hysterectomy) as opposed
to radical approaches in early stage disease [16–19]. The
proponents of simple hysterectomy point to higher risks
of post-surgical morbidity such as lymphedema, uro-
logical and sexual dysfunction and other quality of life
issues. We acknowledge the limitation of our relatively
small sample size in making deductions on the statistical
significance of hysterectomy in improving survival for
early stage ICCs; however, the observed difference in
mean survival time for those who had this intervention
may be clinically significant in settings where no standard
of care is available for treatment of ICCs. This suggested
clinical approach seems sensible in our setting and is
supported by our data showing that only 11 (17.7 %) of
the 62 patients who accepted referral for chemo-radiation
reported receiving this treatment.
The very low completion rate of referrals for chemo-
radiation is of concern. Some of the reasons reported for
not receiving chemo-radiation were summarized above.
They included lack of finances to pay for the service,
and decision to pursue traditional medications or spirit-
ual care at home. These highlight some of the worrisome
social epidemiologic barriers affecting cervical cancer
care in resource limited setting such as Nigeria. Unafford-
able cost, for example, is a pervasive factor hindering
access to essential health services in Nigeria. The current
national health insurance scheme (NHIS) in Nigeria does
not provide coverage for cervical cancer prevention or
treatment, hence most patients incur heavy out-of-pocket
payments [20]. It is likely that high cost of care contrib-
uted to late presentation and related high mortality seen
in this study. Interventions to surmount this and other
barriers to cervical cancer care are needed urgently. We
hope to conduct future qualitative research studies to
better understand these barriers and how we could over-
come them to improve cervical cancer outcome in our
population.
A major strength of our study is the documentation of
follow-up data from diagnosis to death and we utilized
the total accrued follow up time in estimating both the
all-cause mortality rate, the hazard of death and the
survival probabilities in our cohort. However, we also
acknowledge the relatively small cohort size of our study
as a limitation to conducting subgroup analysis to rule
out potential confounding factors on the effect of sur-
gery, chemo-radiation, HIV status and other factors in
predicting cervical cancer survival. We also could not
assess progression-free survival (PFS) in our cohort.
Even though our study focused primarily on all-cause
mortality and survival, we recognize that other outcomes
such as PFS and health-related quality of life are import-
ant in cervical cancer survivors.
Conclusions
In conclusion, our study findings show that cervical can-
cer patients diagnosed at JUTH often have advanced
stage disease and very high rates of death. The comple-
tion rate of referral for chemo-radiation is unpredictably
low and we need to understand and improve the social,
physical and economic barriers to accessing such ser-
vices. Although, it is too early to draw definite conclu-
sions on the effect of simple hysterectomy on survival,
our preliminary data suggests a potential benefit in pa-
tients diagnosed in early cancer stages particularly in our
clinical settings where the optimal standard of care is
often not available. Finally, the high mortality rate seen
in this cohort, represents a clear need for setting up orga-
nized cervical cancer screening which offers opportunities
for detection and treatment of precancerous cervical le-
sions thereby halting progression to invasive cervical can-
cer stages. We also believe that such organized screening
program will provide additional benefits in early detection
of cervical cancer cases which could be treated with im-
proved prognosis for survival.
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